Annovis Bio Inc. (NYSE American: ANVS) Starts Presentation at The LD 500
Annovis Bio Inc. (NYSE American: ANVS) is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. With an aging population, neurodegenerative diseases have become one of the world's largest unmet medical needs. Nerve cell death is the underlying cause of all neurodegenerative disease in both slow chronic and fast acute injuries to the brain. Annovis is developing novel treatments that are expected to improve memory loss and dementia associated with Alzheimer's disease and Alzheimer's in Down Syndrome, as well as body and brain function in Parkinson's disease. Annovis has an ongoing…







